Reccan Diagnostics
Medtech company dedicated to improving the prognosis for patients diagnosed with pancreatic cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | SEK7.0m Valuation: SEK75.0m | Late VC | |
| Total Funding | 000k | ||
| SEK | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (13 %) | - | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 49 % | 87 % | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Reccan Diagnostics is a medtech company focused on improving the prognosis for patients diagnosed with pancreatic cancer. The company is developing and commercializing a highly accurate and easy-to-use blood test for the early detection of pancreatic cancer, targeting patients with elevated risk or those presenting with symptoms. Operating in the healthcare diagnostics market, Reccan aims to address the high mortality rate associated with pancreatic cancer by providing a non-invasive screening method that can detect the disease at an early stage, thereby significantly improving patient outcomes. The business model revolves around the commercialization of this diagnostic test, generating revenue through sales to healthcare providers, hospitals, and diagnostic labs. By offering a quick and reliable method for early detection, Reccan Diagnostics positions itself as a crucial player in the fight against one of the deadliest forms of cancer.
Keywords: pancreatic cancer, early detection, blood test, medtech, non-invasive, healthcare diagnostics, high mortality, patient prognosis, commercialization, innovative screening.